A5051030159- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- 3D Printing in Biomedical Research
- Glycosylation and Glycoproteins Research
- S100 Proteins and Annexins
- Immunotherapy and Immune Responses
- Carbohydrate Chemistry and Synthesis
- Galectins and Cancer Biology
- Adrenal and Paraganglionic Tumors
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Virus-based gene therapy research
- Nanowire Synthesis and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Tissue Engineering and Regenerative Medicine
- Renal and related cancers
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Hormonal Regulation and Hypertension
- Advanced biosensing and bioanalysis techniques
Agency for Science, Technology and Research
2011-2020
Bioprocessing Technology Institute
2004-2020
A*STAR Graduate Academy
2017
Future therapeutic applications of differentiated human embryonic stem cells (hESC) carry a risk teratoma formation by contaminating undifferentiated hESC. We generated 10 monoclonal antibodies (mAbs) against surface antigens hESC, showing strong reactivity undifferentiated, but not The mAbs did cross react with mouse fibroblasts and showed weak to no embryonal carcinoma cells. Notably, one antibody (mAb 84) is cytotoxic hESC NCCIT in concentration-dependent, complement-independent manner....
Abstract The monoclonal antibody mAb 84, which binds to podocalyxin-like protein-1 (PODXL) on human embryonic stem cells (hESCs), was previously reported bind and kill undifferentiated in vitro vivo assays. In this study, we investigate the mechanism responsible for 84-induced hESCs cytotoxicity. Apoptosis likely not cause of 84-mediated cell death because no elevation caspase activities or increased DNA fragmentation observed following incubation with 84. Instead, it preceded by aggregation...
One of the most pertinent concerns using differentiated cells derived from human embryonic stem (hESC) is presence residual undifferentiated hESC, because they carry a risk teratoma formation. A new cell-cell separation approach that eliminates teratoma-forming hESC in order to ensure safer cell therapy was developed. By combining antibodies (IgMs or IgGs) for selective removal magnetic activated sorting (MACS) followed by killing with unique cytotoxic antibody mAb 84, required purity can be...
Embryonic stem cells (ESC) have the unique ability to differentiate into a variety of tissue types. However, realization regenerative medicine will require production large quantities ESC which subsequently be differentiated final phenotype. Thus, we sought develop simple and scaleable bioprocess increase densities achieve this goal. Using mouse embryonic (mESC) as model, by combining automated feeding culture mESC on petriperm dishes, cell were enhanced up 6.4 x 10(6) cells/cm2 compared...
Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider application, especially solid tumours. Here, we describe the development an anti-annexin A2 CAR, CAR(2448), derived from antibody to activity against epithelial ovarian cancer lines. The spacer length CAR(2448) was optimised based on vitro cytotoxic (OC) lines via real-time cytotoxicity assay. longer CAR(2448)L T cells exhibit significant effector...
// Simeon Cua 1 , Heng Liang Tan Wey Jia Fong Angela Chin Ally Lau 2 Vanessa Ding Zhiwei Song 3 Yuansheng Yang 4 and Andre Choo 1, 5 Stem Cells Group, Bioprocessing Technology Institute (BTI), Agency for Science, Research (A*STAR), Singapore 138668, Proteomics Expression Engineering Animal Cell Department of Biomedical Engineering, Faculty National University (NUS), 117575, Correspondence to: Choo, email: andre_choo@bti.a-star.edu.sg Keywords: annexin a2; antibody; antibody-dependent...
This study describes the use of a previously reported chimerised monoclonal antibody (mAb), ch2448, to kill human embryonic stem cells (hESCs) in vivo and prevent or delay formation teratomas. ch2448 was raised against hESCs shown effectively ovarian breast cancer vitro vivo. The antigen target subsequently found be Annexin A2, an oncofetal expressed on both cells. Against cells, binds kills via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-drug conjugate (ADC) routes....
Monoclonal antibodies (mAbs) are used as targeted therapies against cancers. These mAbs kill cancer cells via various mechanisms of actions. In this study, human embryonic stem (hESCs) was the immunogen to generate a panel antibodies. From mAbs, A19 found bind both hESC and cell lines. The antigen target identified Erbb-2 glycan analysis showed that binds N-glycan epitope on antigen. elucidated internalize into following binding hence developed an antibody-drug conjugate (ADC). Using ADC...
Background Adrenocortical carcinoma (ACC) is a rare malignant epithelial tumor originating from adrenocortical cells that carries very poor prognosis. Metastatic or inoperable diseases are often considered incurable, and treatment remains challenge. Especially for advanced cases such as ACC complicated with renal venous cancer thrombus, there few cumulative in the literature. Case summary The patient this case was 39-year-old middle-aged male who admitted to hospital more than half month due...
Abstract Epithelial-mesenchymal transition (EMT) has long been associated with cancer progression and metastasis. As a reversible process, it the potential to be target for therapy. However, this concept of reversing EMT not yet widely explored in current treatment strategies. With identification Nintedanib as an reversal agent, we aim broaden utility triple angiokinase inhibitor by identifying agents that show synergistic lethality it, using monoclonal antibodies (mAbs) combinatory...
Chimeric antigen receptors (CARs) have been a significant focus of cancer therapeutic investigation in recent years, due to the remarkably effective responses observed hematological cancers. However, utility CAR T cells has yet be fully exhibited solid tumours. One key challenges facing treatment tumors with is dearth viable targets, which limits expansion this space.Here, we describe how anti-glycan monoclonal antibody 2448, target annexin A2 on number ovarian and breast cell lines,...
Abstract Chimeric antigen receptors (CARs) have been a significant focus of cancer therapeutic investigation in recent years, due to the remarkably effective responses observed hematological cancers. However, utility CAR T cells has yet be fully exhibited solid tumours. One key challenges facing treatment tumors with is dearth viable targets, which limits expansion this space. Here, we describe how anti-glycan monoclonal antibody 2448, target annexin A2 on number ovarian and breast cell...